Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Major depressive disorder is a chronic condition; its prevalence is expected to grow with the aging trend of high-income countries. Internet-based cognitive-behavioral therapy has proven efficacy in treating major depressive disorder.

Objective: The objective of this study was to assess the cost-effectiveness of implementing a community internet-based cognitive behavioral therapy intervention (Super@, the Spanish program for the MasterMind project) for treating major depressive disorder.

Methods: The cost-effectiveness of the Super@ program was assessed with the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing tool, using a 3-state Markov model. Data from the cost and effectiveness of the intervention were prospectively collected from the implementation of the program by a health care provider in Badalona, Spain; the corresponding data for usual care were gathered from the literature. The health states, transition probabilities, and utilities were computed using Patient Health Questionnaire-9 scores.

Results: The analysis was performed using data from 229 participants using the Super@ program. Results showed that the intervention was more costly than usual care; the discounted (3%) and nondiscounted incremental cost-effectiveness ratios were €29,367 and €26,484 per quality-adjusted life-year, respectively (approximately US $35,299 and $31,833, respectively). The intervention was cost-effective based on the €30,000 willingness-to-pay threshold typically applied in Spain (equivalent to approximately $36,060). According to the deterministic sensitivity analyses, the potential reduction of costs associated with intervention scale-up would reduce the incremental cost-effectiveness ratio of the intervention, although it remained more costly than usual care. A discount in the incremental effects up to 5% exceeded the willingness-to-pay threshold of €30,000.

Conclusions: The Super@ program, an internet-based cognitive behavioral therapy intervention for treating major depressive disorder, cost more than treatment as usual. Nevertheless, its implementation in Spain would be cost-effective from health care and societal perspectives, given the willingness-to-pay threshold of €30,000 compared with treatment as usual.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150403PMC
http://dx.doi.org/10.2196/27410DOI Listing

Publication Analysis

Top Keywords

major depressive
16
internet-based cognitive
12
cognitive behavioral
12
behavioral therapy
12
treating major
12
super@ program
12
usual care
12
willingness-to-pay threshold
12
depressive disorder
8
therapy intervention
8

Similar Publications

[Impact of transcranial magnetic stimulation on depressive symptoms relief in patients with chronic neuropathic pain and comorbid depression: A narrative literature review].

Encephale

September 2025

Centre de référence régional des pathologies anxieuses et de la dépression, pôle de psychiatrie générale et universitaire, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Inserm U1215, Neurocentre Magendie, 33000 Bordeaux, France. Electronic address:

Neuropathic pain results from an injury or a dysfunction of the somatosensory system. Management of this disease is complex due to a restricted therapeutic arsenal and limited efficacy of currently available treatments. Because of its chronic and disabling nature, neuropathic pain is strongly associated with depressive disorders.

View Article and Find Full Text PDF

Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.

Am J Geriatr Psychiatry

August 2025

Mood Disorder and Psychopharmacology Unit (RS, JKT, CED, RSM), University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronnto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@

Ketamine has emerged as a promising treatment for major depression, though its efficacy and safety remain incompletely characterized in older adults. This systematic review synthesizes current evidence for ketamine in geriatric depression. A search of PubMed, EMBASE, and PsycINFO was conducted.

View Article and Find Full Text PDF

Is the Time Right to Start Testing if Late-Onset Depression is Associated With the Development of an α-Synucleinopathy Like Parkinson's Disease? A Double Systematic Review and Meta-Analysis.

Am J Geriatr Psychiatry

August 2025

Department of Psychiatry (MLO, SEC, JZ, KS), Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Neuroimmunology Research Group (KS), Netherlands Institute for Neuroscience, Amsterdam, The Netherlands; Psychiatric Program of the Netherlands Brain Bank (KS), Ne

Parkinson's disease (PD) is characterized by two neurobiological markers: pathological α-synuclein and/or a dopaminergic deficit. Depression is common in PD, and may precede motor signs, particularly in late-onset depression (LOD). We conducted two systematic reviews and a meta-analysis to examine the relationship between depression and PD development.

View Article and Find Full Text PDF

Developing Clinically Interpretable Neuroimaging Biotypes in Psychiatry.

Biol Psychiatry

September 2025

Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, 94304, USA. Electronic address: leawillia

Despite available treatments, major depressive disorder (MDD) remains one of the leading causes of disability across medical conditions. The current symptom-based diagnostic system groups patients with highly heterogeneous presentations, with no biomarkers to guide treatment-akin to diagnosing heart disease solely by chest pain, without imaging to reveal the underlying pathology. Lacking biological guidance, clinicians rely on trial-and-error prescribing.

View Article and Find Full Text PDF

Blood transcriptomic analysis reveals a distinct molecular subtype of treatment resistant depression compared to non-treatment resistant depression.

Brain Behav Immun

September 2025

Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology (BIST), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; Biomedical Research Networking Center for Rare Diseases (CIBERER), Barcelona 08003, Spain.

Treatment-resistant depression (TRD) is a severe condition characterized by chronic and recurrent depressive symptoms, leading to significant morbidity and a considerable socio-economic impact. Genetic and biological studies suggest that TRD is associated with distinct biological characteristics. In this study, we analysed whole-transcriptome differences in 293 patients with major depressive disorder (MDD) to compare TRD (N = 150) vs non-TRD (N = 143) cases.

View Article and Find Full Text PDF